United States Patent 8,617,591: Rotigotine Transdermal Delivery System Patent Scope and Landscape

US Patent 8,617,591 protects a specific rotigotine transdermal patch architecture designed to control crystallization and drug release. Its core limitations are: free-base rotigotine contained in microreservoirs; a semi-permeable adhesive polymer matrix; limited protonated rotigotine in that matrix; selective permeability to unprotonated rotigotine; and tightly defined microreservoir dimensions.

The patent is directed to product composition, patch structure, and treatment methods. A competing patch would face substantial infringement risk if it uses the claimed microreservoir-and-silicone-adhesive configuration, even if it changes the manufacturing sequence or omits certain dependent-claim excipients.

What does US Patent 8,617,591 protect?

US 8,617,591 protects a rotigotine transdermal delivery system, or TDS, having two principal components:

A self-adhesive, solid or semi-solid polymer matrix.
Microreservoirs containing rotigotine in its free-base form.

The matrix must also satisfy a chemical selectivity requirement. It can contain up to approximately 10% by weight of protonated rotigotine, while remaining permeable to unprotonated rotigotine and substantially impermeable to protonated rotigotine.

The claims therefore cover more than a generic rotigotine patch. They require a defined physical distribution of free-base drug inside an adhesive matrix and a defined relationship between matrix permeability, protonation state, and microreservoir size.

Patent identification

Field	Information
Patent	US 8,617,591 B2
Subject	Rotigotine transdermal delivery system
Technology	Adhesive matrix patch with rotigotine microreservoirs
Patent type	Utility patent
Grant date	December 31, 2013
Patent holder / applicant	UCB-affiliated pharmaceutical entities
Active pharmaceutical ingredient	Rotigotine
Dosage form	Transdermal patch
Principal commercial product	Neupro
Core claims	Product, formulation, manufacturing alternatives, and treatment methods
Nominal statutory term	Generally 20 years from the earliest effective nonprovisional or international filing date, subject to patent-term adjustments and other term rules

The patent should be reviewed with its prosecution history, assignment records, terminal-disclaimer records, maintenance-fee records, and Orange Book listing history before making a final freedom-to-operate or litigation decision. The issued claims alone do not establish current enforceability.

What are the independent claims in US 8,617,591?

The patent has four material independent claims: claims 1, 15, 27, and 29.

Claims 1 and 15: product claims

Claims 1 and 15 independently cover a transdermal delivery system comprising:

A self-adhesive matrix with a defined thickness.
A backing layer.
A solid or semi-solid semi-permeable polymer matrix.
Microreservoirs containing rotigotine free base.
Up to approximately 10% w/w protonated rotigotine in the polymer matrix.
Permeability to unprotonated rotigotine.
Substantial impermeability to protonated rotigotine.

The principal difference is the microreservoir size metric:

Claim	Microreservoir limitation
Claim 1	Maximum diameter up to 70% of matrix thickness
Claim 15	Mean diameter from 1% to 40% of matrix thickness

Claim 1 is focused on the largest reservoir dimension. Claim 15 is focused on average reservoir size. A product might avoid one metric while still satisfying the other, depending on the reservoir-size distribution and the applicable claim construction.

Claims 27 and 29: method-of-treatment claims

Claims 27 and 29 cover applying the claimed TDS to the skin of a patient suffering from a disease treatable with rotigotine.

Claims 28 and 30 narrow the disease to Parkinson’s disease.

These claims require use of a patch meeting the limitations of claim 1 or claim 15. They do not independently cover every method of administering rotigotine through the skin.

How do the microreservoir limitations affect infringement?

The microreservoir limitations are central to claim scope and likely to infringement analysis.

Maximum-diameter branch

Claim 1 reaches systems in which the maximum diameter of a microreservoir is no more than 70% of the adhesive-matrix thickness. Dependent claims narrow this requirement to:

5% to 60% of matrix thickness under claim 2.
Up to 35 micrometers under claim 3.

The claim uses a relative dimension and, in claim 3, an absolute dimension. A competitor would need reliable microscopy and cross-sectional measurement data to determine whether its product meets these limitations.

Mean-diameter branch

Claim 15 requires a mean microreservoir diameter of 1% to 40% of matrix thickness. Dependent claims narrow the range to:

1% to 20% under claim 16.
Approximately 0.5 to 20 micrometers under claim 17.

The mean-diameter requirement creates methodological issues. In an infringement dispute, the parties could contest:

Whether the mean is arithmetic, geometric, or otherwise calculated.
Whether the measurement is based on area, volume, or a representative cross-section.
How irregular or coalesced reservoirs are counted.
Whether the matrix thickness is measured before or after application to skin.
Whether reservoir outliers control the maximum-diameter analysis.

These issues make product characterization important. A patch that uses dispersed drug domains but does not describe them as “microreservoirs” could still fall within the claims if the physical structure satisfies the limitations.

What chemical and formulation features are required?

The claims impose a specific protonation and permeability relationship.

Protonated rotigotine limit

The polymer matrix may contain up to about 10% w/w protonated rotigotine. Claims 4 and 18 narrow the concentration to greater than 5% through about 10%.

This limitation distinguishes the claimed matrix from formulations in which rotigotine is predominantly present as a salt throughout the adhesive phase. The claims permit some protonated rotigotine but require the matrix to remain selectively permeable to unprotonated rotigotine.

Free-base rotigotine

The microreservoirs must comprise rotigotine as free base. Claims 5 and 19 cover free base produced in situ. Claims 6 and 20 cover free base isolated before incorporation into the matrix.

These alternatives prevent a straightforward design-around based only on manufacturing sequence. Both in situ generation and prior isolation are expressly addressed.

Silicone pressure-sensitive adhesive

Claim 7 and claim 21 require a silicone-containing pressure-sensitive adhesive. Claim 8 further covers two or more silicone-containing pressure-sensitive adhesives.

Claim 9 identifies a blend of:

A high-tack silicone adhesive comprising polysiloxane with resin.
A medium-tack silicone adhesive comprising polysiloxane with resin.

A competing formulation that replaces the silicone adhesive with an acrylic, rubber-based, polyurethane, or other non-silicone adhesive may have a stronger noninfringement position against these dependent claims. It could still face claims 1 or 15 if the broader polymer-matrix limitations are met.

What dependent claims cover microreservoir density and crystallization control?

Claims 10 through 14 and 22 through 26 cover structural density, interfacial materials, and crystallization inhibitors.

Claims	Protected feature
10, 22	10³ to 10⁹ microreservoirs per cm²
11, 23	10⁶ to 10⁹ microreservoirs per cm²
12, 24	No particles that absorb rotigotine salts at the TDS/skin interface
13, 25	Specified crystallization inhibitors
14, 26	Soluble polyvinylpyrrolidone

The crystallization-inhibitor claims cover soluble polyvinylpyrrolidone, a polyvinylpyrrolidone-vinyl acetate copolymer, polyethylene glycol, polypropylene glycol, glycerol, selected glycerol fatty-acid esters, and ethylene-vinyl acetate copolymer.

These claims are commercially relevant because rotigotine stability and crystallization control are important patch-development constraints. A generic developer may avoid a particular dependent claim by selecting a different inhibitor, but the alternative must still be evaluated against the independent microreservoir, protonation, permeability, and size limitations.

How broad are the product claims?

The product claims are technically narrow but commercially meaningful.

A product must satisfy all limitations of an independent claim. The following differences alone may not avoid infringement:

A different patch size.
A different rotigotine loading.
A different backing layer.
A different reservoir-production sequence.
Use of free base made in situ rather than isolated free base.
Use of a different crystallization inhibitor, if the independent claim is still met.
Use of a different trade name or device format.

Potentially meaningful design-around positions include:

Eliminating discrete microreservoirs and using a genuinely homogeneous drug-in-adhesive system.
Using rotigotine salt rather than free-base rotigotine in the claimed microreservoir structure.
Using a matrix that is not substantially impermeable to protonated rotigotine.
Using a non-self-adhesive drug reservoir with a separate adhesive layer.
Using reservoir dimensions outside both the maximum-diameter and mean-diameter limitations.
Using a polymer system that does not meet the claimed semi-permeability characteristics.

Each position depends on technical evidence. Labels such as “drug-in-adhesive” or “matrix patch” do not determine claim scope by themselves.

What patent landscape surrounds rotigotine transdermal patches?

The rotigotine patent landscape has several layers.

Foundational rotigotine and transdermal patents

Earlier patents relating to rotigotine generally address:

Rotigotine as a dopamine agonist.
Therapeutic use in Parkinson’s disease and related disorders.
Transdermal administration.
Adhesive patch construction.
Drug delivery rates and dosing.

US 8,617,591 is more formulation-specific. It focuses on microreservoir distribution, free-base rotigotine, selective permeability, protonated rotigotine content, and crystallization control.

Commercial-product protection

Neupro is the principal commercial product associated with rotigotine transdermal delivery. FDA labeling identifies rotigotine as the active ingredient and describes once-daily transdermal administration for Parkinson’s disease and restless legs syndrome (U.S. Food and Drug Administration, 2023).

The commercial protection package may include separate patents directed to:

Rotigotine composition or salts.
Transdermal systems.
Adhesive compositions.
Manufacturing processes.
Stability and crystallization control.
Method of treatment.
Pediatric or regulatory exclusivity.

US 8,617,591 should therefore be treated as one layer of the estate rather than as the entire Neupro exclusivity position.

What is the FDA and Orange Book status of US 8,617,591?

Neupro was approved by the FDA under NDA 021829. FDA approval covers transdermal rotigotine for Parkinson’s disease and moderate-to-severe primary restless legs syndrome, subject to the approved labeling and dosage strengths (FDA, 2023).

The Orange Book should be checked for:

Whether US 8,617,591 is listed against NDA 021829.
The listed patent expiration date.
Whether the listing covers the drug substance, drug product, or method of use.
Any paragraph IV certification activity.
Any pediatric exclusivity extension.

The patent’s issued product claims are formulation and device claims. If listed, an ANDA applicant may need to provide a paragraph IV certification or a section viii statement, depending on the scope of the listed claim and the proposed labeling.

A section viii carve-out may be difficult if the listed claims cover the patch itself rather than only a Parkinson’s disease indication. Conversely, method claims limited to Parkinson’s disease may be more susceptible to labeling-based analysis than product claims.

When does US 8,617,591 lose exclusivity?

The nominal patent term depends on the earliest effective filing date and any patent-term adjustment. A patent granted from a U.S. national-stage or related application generally expires 20 years from the applicable earliest nonprovisional or international filing date, not 20 years from the grant date.

The practical exclusivity date must be determined from:

The face of the patent.
USPTO Patent Center.
Any patent-term adjustment.
Any terminal disclaimer.
Maintenance-fee status.
FDA Orange Book listing data.
Pediatric exclusivity, if applicable.

Because the patent was granted on December 31, 2013, its term is not measured as 20 years from that date. The relevant nominal expiry is in the mid-to-late 2020s, subject to the official term calculation.

Which companies are challenging rotigotine patent protection?

Public generic competition for Neupro requires analysis of ANDA filings, paragraph IV notices, district-court complaints, and Federal Circuit proceedings. The principal competitive threat would come from companies developing generic rotigotine transdermal systems rather than biosimilar manufacturers.

Rotigotine is a small molecule, so the relevant FDA pathway is an ANDA, not a biosimilar application under the Public Health Service Act. A generic applicant would need to address:

Active-ingredient sameness.
Patch design and dosage form.
Bioequivalence.
Adhesion performance.
Drug release.
Crystallization and stability.
Listed patents.
Any formulation-specific infringement risk.

No biosimilar pathway applies to Neupro.

What litigation and settlement issues matter?

The central litigation risks would involve claim construction and proof of physical structure. Likely disputes include:

Whether a formulation contains “microreservoirs.”
Whether the matrix is “substantially impermeable” to protonated rotigotine.
How protonated rotigotine is quantified.
How reservoir diameter and matrix thickness are measured.
Whether a product satisfies the maximum-diameter limitation, the mean-diameter limitation, or both.
Whether the accused adhesive is silicone-containing.
Whether a claimed inhibitor is present in the relevant concentration or form.

A paragraph IV case could produce an automatic 30-month stay if the statutory requirements are met. Settlement terms could include a license, an agreed generic launch date, supply arrangements, or restrictions on the proposed formulation. The existence and terms of any settlement must be verified from the relevant court docket and FDA records rather than inferred from the patent grant.

How strong is the patent estate for Neupro?

US 8,617,591 has meaningful strength against a close copy of the commercial formulation because it combines multiple technical limitations that may be difficult to avoid simultaneously:

Free-base rotigotine.
Discrete microreservoirs.
A semi-permeable adhesive matrix.
Selective permeability based on protonation state.
Defined reservoir size relative to matrix thickness.
Optional silicone adhesive and crystallization-control limitations.

Its weakness is claim specificity. A competitor that develops a genuinely different delivery architecture may avoid the claims more readily than a competitor that reproduces the microreservoir formulation.

The strongest claims for enforcement are likely the independent product claims if the accused patch’s physical construction can be characterized. The method claims may have narrower practical value because enforcement requires proof of use and may be affected by prescribing, labeling, and induced-infringement issues.

How does US 8,617,591 compare with a conventional drug-in-adhesive patch?

Issue	US 8,617,591 architecture	Conventional homogeneous matrix patch
Drug distribution	Microreservoirs containing free base	Drug dispersed through adhesive
Matrix	Semi-permeable polymer matrix	May not have selective permeability
Protonated drug	Up to about 10% in matrix	May be present throughout formulation
Adhesive	Silicone adhesive expressly claimed in dependent claims	May be acrylic, silicone, or rubber-based
Reservoir dimensions	Expressly limited	Usually not applicable
Crystallization control	Specified inhibitors covered	May use different stabilization strategy
Main infringement risk	High if the microreservoir structure is replicated	Lower if no microreservoirs exist

Key Takeaways

US 8,617,591 is a formulation and device patent for rotigotine transdermal systems.
Claims 1 and 15 are the principal product claims.
Claims 27 and 29 cover treatment methods using the claimed patch.
The core invention is the combination of free-base rotigotine microreservoirs and a selectively permeable adhesive matrix.
Microreservoir size is defined both by maximum diameter and by mean diameter.
Silicone adhesives, reservoir density, interfacial particle restrictions, and crystallization inhibitors are covered by dependent claims.
A conventional homogeneous drug-in-adhesive patch may have a stronger design-around position than a patch replicating the claimed microreservoir architecture.
Rotigotine is a small molecule; generic competition proceeds through the ANDA pathway, not the biosimilar pathway.
FDA and Orange Book records are required to establish the definitive listed-patent and current exclusivity position.
Patent expiry must be calculated from the effective filing date and adjusted for any patent-term adjustment, terminal disclaimer, or pediatric exclusivity.

FAQs

Does US 8,617,591 cover all rotigotine patches?

No. It covers patches meeting the specific free-base microreservoir, semi-permeable matrix, protonation, permeability, and size limitations in the claims.

Can a rotigotine patch avoid the patent by using an acrylic adhesive?

Possibly, particularly against dependent claims requiring a silicone-containing pressure-sensitive adhesive. The independent claims still require analysis of the complete matrix and microreservoir structure.

Does producing rotigotine free base in situ avoid infringement?

No. Claims 5 and 19 expressly cover in situ production, while claims 6 and 20 cover free base isolated before incorporation.

Are rotigotine generics biosimilars?

No. Rotigotine is a chemically synthesized small molecule. Generic transdermal rotigotine products use the ANDA pathway.

What evidence is most important in a patent dispute involving this patent?

The key evidence includes cross-sectional microscopy, reservoir-size distributions, matrix-thickness measurements, chemical analysis of protonated and unprotonated rotigotine, permeability data, adhesive composition records, and manufacturing documents.

References

U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,617,591 B2: Transdermal delivery system comprising rotigotine.
U.S. Food and Drug Administration. (2023). Neupro (rotigotine) transdermal system prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
U.S. Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent No. 8,617,591.
U.S. Code, Title 35, §§ 154, 271, and 282.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	02016860	Jul 30, 2002

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	322263	⤷ Start Trial
Australia	2003258539	⤷ Start Trial
Brazil	0313091	⤷ Start Trial
Canada	2491366	⤷ Start Trial
China	101953819	⤷ Start Trial
China	1671375	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,617,591

Summary for Patent: 8,617,591